RTI uses cookies to offer you the best experience online. By clicking “accept” on this website, you opt in and you agree to the use of cookies. If you would like to know more about how RTI uses cookies and how to manage them please view our Privacy Policy here. You can “opt out” or change your mind by visiting: http://optout.aboutads.info/. Click “accept” to agree.
Dose optimization of inhaled tigecycline in humans to overcome inherent adverse events and maximize bacterial clearance using a physiologically-based pharmacokinetic modeling approach
Park, H., Singh, A., Srivastava, A., Thalluri, B., Mathieu, C., Gupta, P., Pearce, C., Zohaib Ali, M., Alshiraihi, I., Maloney Norcross, S. E., Hickey, A. J., Gonzalez-Juarrero, M., & Meibohm, B. (2026). Dose optimization of inhaled tigecycline in humans to overcome inherent adverse events and maximize bacterial clearance using a physiologically-based pharmacokinetic modeling approach. Frontiers in Tuberculosis, 4. https://doi.org/10.3389/ftubr.2026.1762713
RTI shares its evidence-based research - through peer-reviewed publications and media - to ensure that it is accessible for others to build on, in line with our mission and scientific standards.
